Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Tumor angiogenesis
3. Tumor metastasis
4. Vascular vs. lymphatic system
5. Capillary ultrastructure
6. Immunostained blood and lymphatic vessels
7. Differences between BEC and LEC
8. VEGF and VEGFR tyrosine kinase
9. VEGFR - 1, 2 and 3
10. Schematic structure of VEGF
11. What is VEGF?
12. VEGF family tree
13. Signaling via receptor tyrosine kinase (1)
14. Signaling via receptor tyrosine kinase (2)
15. Role of VEGFR-1 in angiogenesis
16. Biological role of VEGF
17. VEGF in embryonic angiogenesis
18. VEGF in angiogenesis during development
19. Physiological angiogenesis in the adult
20. VEGFR-4
21. VEGF-C role in development of lymphatics
22. Embryonic formation of the lymphatic vasculature
23. Tumor growth and angiogenesis
24. Tumor angiogenesis by vascular sprouting
25. VEGF promotes tumor angiogenic switch
26. Angiogenesis role in tumor progression
27. Tumor characteristics promote VEGF expression
28. Tumor hypoxia induce VEGF expression
29. VEGF overexpression and abnormal vasculature
30. Abnormal blood vessel organization in tumors
31. Abnormal tumor vasculature
32. Normal vs. tumor vasculature
33. VEGF induces increased permeability
34. VEGF makes tumor blood vessels leaky

Topics Covered

• Vascular Endothelial Growth Factors (VEGF)
• Inhibition of VEGF action to control tumor angiogenesis
• VEGFs and VEGF receptor tyrosine kinases
• Structure of VEGF
• Signaling through a receptor tyrosine kinase
• Role of VEGFR-1 in angiogenesis
• Biological role of VEGF
• VEGF in embryonic angiogenesis
• Role of VEGF in physiological angiogenesis both during development and in the adult
• Roles of VEGFR-3 and VEGF-C in the early phases of development
• Mechanism of VEGF-C action in lymphatic development
• Tumor angiogenesis
• Result of overexpression of VEGF in tissues

Links

Series:

• Signal Transduction via Protein Tyrosine Kinase Receptors

Categories:

• Biochemistry

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Prof. Kari Alitalo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.